Quality-of-life evaluation for advanced non-small-cell lung cancer: a comparison between vinorelbine plus gemcitabine followed by docetaxel versus paclitaxel plus carboplatin regimens in a randomized trial: Japan Multinational Trial Organization LC00-03 (BRI LC03-01)

BMC Cancer

Research Article

Hideki Origasa¹  Harue Tada²  Satoshi Teramukai²  Kaoru Kubota³  Tetsu Shinkai⁴  Akihiro Tokoro⁵  Masaaki Kawahara⁶  Kiyoyuki Furuse⁷  Masanori Fukushima⁸ 

[1] Department of Biostatistics and Clinical Epidemiology, University of Toyama Graduate School, 2630 Sugitani, 930-0194, Toyama, Japan;Department of Clinical Trial Design and Management, Translational Research Center, Kyoto University Hospital, 54 Shogoin Kawahara-cho, Sakyo-ku, 606-8507, Kyoto, Japan;National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, 104-0045, Tokyo, Japan;National Hospital Organization Shikoku Cancer Center, 160 Minami Umemoto-cho, 791-0280, Matsuyama, Japan;National Hospital Organization, Kinki-chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, 591-8555, Sakai, Japan;Otemae Hospital, 1-5-3 Otemae, Chuo-ku, 540-0008, Osaka, Japan;The Japan Multinational Trial Organization, 474 Uehonnojimae-cho, Teramachi-Oike agaru, 604-0925, Nakagyo-ku, Kyoto, Japan;Translational Research Informatics Center, 1-5-4 Minatojima-minamimachi, 650-0047, Chuo-ku, Kobe, Japan;

关键词: Metastatic NSCLC;    Chronic Illness Therapy;    Trial Outcome Index;    Spirituality Subscale;    Lung Cancer Subscale;   

DOI  :  10.1186/1471-2407-11-356

 received in 2010-07-30, accepted in 2011-08-17,  发布年份 2011

来源: Springer

【 摘 要 】

BackgroundA randomized trial of vinorelbine plus gemcitabine followed by docetaxel (VGD) versus paclitaxel plus carboplatin (PC) in patients with advanced non-small-cell lung cancer showed no difference in overall survival (median survival time: 13.6 versus 14.1 months) between the two treatment groups. We report here the results of quality-of-life (QOL) study initiated in the mid-course of this randomized trial.MethodsThe patients themselves assessed the Functional Assessment of Cancer Therapy (FACT)-Lung (FACT-L), FACT-Taxane and the Functional Assessment of Chronic Illness Therapy - Spirituality (FACIT-Sp) QOL instruments at baseline and 6, 12 and 18 weeks after the treatment. The primary endpoint was a comparison of total QOL score for each assessment instrument between the two groups.ResultsSixty-eight patients from the trial (VGD, 34; PC, 34) who submitted baseline questionnaires and at least one questionnaire over the course of treatment were eligible. Longitudinal analysis showed a significant difference in slope of the FACT-Taxane score (p = 0.004) between treatment regimens over time, but no difference was found in FACT-L score (p = 0.311) and FACIT-Sp score (p = 0.466) between the two groups.ConclusionsThe significant difference in slope of FACT-Taxane score favored the VGD regimen. These data should be considered in treatment decision-making for patients with advanced non-small-cell lung cancer.Trial registrationNCT00242983.

【 授权许可】

CC BY   
© Kawahara et al; licensee BioMed Central Ltd. 2011